DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Once Weekly D-cycloserine for Schizophrenia

Information source: Massachusetts General Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Schizophrenia

Intervention: D-cycloserine (Drug); Placebo (Drug)

Phase: Phase 4

Status: Withdrawn

Sponsored by: Massachusetts General Hospital

Official(s) and/or principal investigator(s):
Donald C Goff, M.D., Principal Investigator, Affiliation: Massachusetts General Hospital

Summary

This is a parallel-group, placebo-controlled trial examining the cognitive effects at weeks 1, 4, & 8 of once-weekly oral D-cycloserine 50 mg added to a stable dose of antipsychotic for 8 weeks in adult outpatients with schizophrenia.

Clinical Details

Official title: Effects of Weekly Dosing of D-cycloserine on Cognitive Function in Individuals With Schizophrenia.

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Effect of repeated weekly dosing of D-cycloserine on performance on a standard cognitive battery.

Secondary outcome:

Effects of weekly D-cycloserine dosing on negative symptoms at weeks 4 & 8 compared to placebo.

Effect of a single dose of D-cycloserine 50 mg on memory consolidation as measured by the Logical Memory Test compared to placebo.

Assess the persistence of once-weekly D-cycloserine effects on memory consolidation measured at weeks 4 & 8.

Assess tolerability and side effects of weekly D-cycloserine compared to placebo

Detailed description: In a previous placebo-controlled trial, investigators demonstrated significant improvement of negative symptoms with once-weekly D-cycloserine treatment. In addition, investigators found significant improvement of memory consolidation following the first dose; however, the effect on memory consolidation was lost after several weeks. The "practice effect" of weekly measurement of memory consolidation using repeated administration of the Logical Memory Test may have resulted in a "ceiling effect" which would obscure drug/placebo differences. In the current study, investigators propose to administer the Logical Memory Test at four-week intervals (weeks 1, 4 and 8) to avoid the ceiling effect. Additionally a measurement will be added of negative symptoms at week 4 to better characterize the time course of negative symptom improvement. Hypotheses: 1. Assess the effects of a single dose of D-cycloserine 50 mg on memory consolidation as measured by the Logical Memory Test compared to placebo. 2. Assess the persistence of once-weekly D-cycloserine effects on memory consolidation measured at weeks 4 & 8. 3. Assess the effects of repeated weekly dosing of D-cycloserine on performance on a standard cognitive battery at week 8 compared to placebo. 4. Assess effects of weekly D-cycloserine dosing on negative symptoms at weeks 4 & 8 compared to placebo. 5. Assess tolerability and side effects of weekly D-cycloserine compared to placebo.

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria: 1. Male or female 2. Age 18-65 years 3. Diagnosis of schizophrenia or schizoaffective disorder, depressed type 4. Stable dose of antipsychotic for at least 4 weeks. 5. Able to provide informed consent 6. Able to complete a cognitive battery Exclusion Criteria: 1. Current treatment with clozapine 2. Dementia 3. Seizure disorder 4. Unstable medical illness 5. Active substance abuse 6. Pregnancy, nursing, or unwilling to use appropriate birth control measures during participation if female and fertile. 7. Severe renal insufficiency (Serum creatinine > 1. 5 mg/dL)

Locations and Contacts

Massachusetts General Hospital, Boston, Massachusetts 02114, United States
Additional Information

Starting date: July 2009
Last updated: November 19, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017